医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sumitomo Heavy Industries, Ltd. Obtains Medical Device Approval for Manufacturing and Sales of Accelerator Based BNCT System and the Dose Calculation Program in Japan

2020年03月12日 PM03:11
このエントリーをはてなブックマークに追加


 

TOKYO

Sumitomo Heavy Industries, Ltd. (TOKYO:6302)(President: Shinji Shimomura, referred as SHI hereinafter) has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using an accelerator (cyclotron), targeting carcinoma of the head and neck region in collaboration with STELLA PHARMA CORPORATION (President: Tomoyuki Asano). And SHI has applied the system for new medical device approval on 11th October, 2019. Today, we would like to announce that Sumitomo Heavy Industries, Ltd. obtains new medical device approval for manufacturing and sales of accelerator based BNCT system (NeuCureTM System) and the dose calculation program (NeuCureTM Dose Engine) from Japanese Ministry of Health, Labor and Welfare. These are the world’s first medical devices for BNCT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005853/en/

Accelerator based BNCT system and its cyclotron (Graphic: Business Wire)

Accelerator based BNCT system and its cyclotron (Graphic: Business Wire)

Market and SHI’s target

BNCT is unique radiation therapy method which is led by Japanese researchers. SHI believes better treatment will be provided to patients in the world. Once STELLA PHARMA CORPORATION obtains the drug application approval, SHI would like to develop BNCT market globally together with partners by means of sending information of BNCT and the clinical outcome to the world. It may take years for obtaining global common recognition. However, SHI would like to install more than 100 systems globally as a long term target. SHI will keep making efforts to improve and develop NeuCureTM system and NeuCureTM Dose Engine.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005853/en/

CONTACT

Sumitomo Heavy Industries, Ltd.

Corporate Communication Dept.

Takuto Ono, +81-3-6737-2332

shi.zshi_koho@shi-g.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • TIENS Group will Become a Global Participant in the Future Massive Health Industry
  • エンヨ・ファーマがB型慢性肝炎患者でVonafexor(EYP001)を検討中の第2a相試験2件から得た16週目のトップライン中間解析結果を発表
  • Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market
  • WNS Launches PRECIZON to Deliver Cloud-based Competitive Intelligence for Life Sciences Industry
  • Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study